Cogentix Medical, Inc. (NASDAQ:CGNT) Earns Buy Rating from Analysts at Roth Capital

Equities research analysts at Roth Capital initiated coverage on shares of Cogentix Medical, Inc. (NASDAQ:CGNT) in a note issued to investors on Wednesday, November 8th, MarketBeat.com reports. The brokerage set a “buy” rating and a $4.00 price target on the medical device company’s stock. Roth Capital’s price target suggests a potential upside of 40.35% from the company’s current price.

Several other equities analysts have also commented on the company. JMP Securities began coverage on Cogentix Medical in a research note on Friday, October 6th. They issued an “outperform” rating and a $5.00 target price for the company. Zacks Investment Research upgraded Cogentix Medical from a “hold” rating to a “buy” rating and set a $2.50 target price for the company in a research note on Friday, August 4th.

Shares of Cogentix Medical (NASDAQ:CGNT) opened at $2.85 on Wednesday. Cogentix Medical has a 12-month low of $1.55 and a 12-month high of $3.26.

Large investors have recently added to or reduced their stakes in the business. Northern Trust Corp increased its position in Cogentix Medical by 0.4% in the 2nd quarter. Northern Trust Corp now owns 73,926 shares of the medical device company’s stock valued at $129,000 after acquiring an additional 326 shares during the period. Renaissance Technologies LLC increased its position in Cogentix Medical by 2.3% in the 1st quarter. Renaissance Technologies LLC now owns 562,996 shares of the medical device company’s stock valued at $1,013,000 after acquiring an additional 12,459 shares during the period. Dimensional Fund Advisors LP acquired a new stake in Cogentix Medical in the 3rd quarter valued at approximately $152,000. Finally, Broadfin Capital LLC increased its position in Cogentix Medical by 45.2% in the 2nd quarter. Broadfin Capital LLC now owns 1,094,544 shares of the medical device company’s stock valued at $1,905,000 after acquiring an additional 340,771 shares during the period. 13.33% of the stock is currently owned by institutional investors.

COPYRIGHT VIOLATION WARNING: This article was first reported by BBNS and is the property of of BBNS. If you are accessing this article on another domain, it was illegally copied and reposted in violation of U.S. & international copyright & trademark law. The legal version of this article can be viewed at https://baseballnewssource.com/markets/roth-capital-initiates-coverage-on-cogentix-medical-inc-cgnt/1767955.html.

About Cogentix Medical

Cogentix Medical, Inc is a global medical device company. The Company designs, develops, manufactures and markets a line of fiber-optic and video endoscopy products under the PrimeSight brand that are used across various surgical specialties in diagnostic and treatment procedures. The Company also offers the Urgent PC Neuromodulation System (Urgent PC Systems), a device that delivers percutaneous tibial nerve stimulation (PTNS), for the office-based treatment of overactive bladder (OAB).

Receive News & Ratings for Cogentix Medical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cogentix Medical Inc. and related companies with our FREE daily email newsletter.

 


Latest News

Phillies Sign Free Agent Carlos Santana
Phillies Sign Free Agent Carlos Santana
Tigers Trade Ian Kinsler to Angels for Pair of Minor Leaguers
Tigers Trade Ian Kinsler to Angels for Pair of Minor Leaguers
Manny Machado Could Change Positions or Uniforms
Manny Machado Could Change Positions or Uniforms
Jack Morris, Alan Trammel Voted by Modern Era Committee into Hall of Fame
Jack Morris, Alan Trammel Voted by Modern Era Committee into Hall of Fame
Yankees and Marlins Continue Stanton Trade Talks
Yankees and Marlins Continue Stanton Trade Talks
Marlins Making Moves, Trade Dee Gordon to Seattle
Marlins Making Moves, Trade Dee Gordon to Seattle


Leave a Reply

 
© 2006-2017 BBNS.